The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / RheumPAC: Answers to FAQs

RheumPAC: Answers to FAQs

September 17, 2017 • By From the College

  • Tweet
  • Email
Print-Friendly Version / Save PDF

What is RheumPAC?

RheumPAC is the ACR’s nonpartisan political action committee (PAC) that works to elect and support pro-rheumatology candidates. It is the only PAC dedicated to the interests of the rheumatology profession. RheumPAC was created 10 years ago with the mission of educating, electing and supporting federal lawmakers who understand and can positively address the issues that impact rheumatology care providers and their patients.

You Might Also Like
  • What Is RheumPAC?
  • RheumPAC Advances Policy Issues of Rheumatology Professionals
  • RheumPAC: The Voice of the ACR
Explore This Issue
September 2017
Also By This Author
  • Avoid Billing Risks for New vs. Established Patients

Why does the ACR need RheumPAC?

Under federal law, the ACR/ARHP is prohibited from using its general treasury funds to make contributions in connection with federal elections. However, the ACR/ARHP is permitted to form a PAC to provide members with the opportunity to legally and ethically participate in federal election activities. RheumPAC creates opportunities to educate and develop relationships with members of Congress, as well as support champions for our issues and our message. It is the financial vehicle through which ACR and ARHP members can support Congressional candidates who share our commitment to rheumatology.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Why do ACR & ARHP members contribute?

Congress enacts health policies that directly affect our profession and our patients. RheumPAC creates opportunities for the ACR to educate key policymakers on the importance and value of rheumatology. RheumPAC needs your support in order to increase and expand the ACR’s advocacy efforts. We can only be effective when legislators understand the extent and impact of rheumatology-related policy issues.

We often hear, “I don’t get involved in politics.” We are already involved. Elected legislators make policy every day that directly impacts our profession, our livelihoods and our ability to care for our patients. The question is whether or not the ACR and ARHP have a seat at the table for these discussions.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Who receives RheumPAC funds?

Candidates are recommended for support by ACR/ARHP members and our advocacy staff. We consider many factors for candidate contributions (e.g., voting record, committee assignments, leadership, number of members in district, etc.) and make funding recommendations based on available resources. The RheumPAC Committee reviews these recommendations and has final approval of the list of supported candidates. RheumPAC is bipartisan and determines candidates’ eligibility for support based on their past support for policies that directly impact rheumatology or their ability to further our goals in their position in Congress. All U.S. ACR and ARHP members are welcome to suggest candidates for support.

We often hear, “PACs exist only to help one party or another.” Untrue. RheumPAC is truly bipartisan, our only political affiliation is to further the ACR’s and ARHP’s policies. Don’t believe it? Visit the RheumPAC section of the ACR website, which is updated quarterly to list candidates who receive RheumPAC funds every quarter.

Who can contribute to RheumPAC?

U.S. citizens or permanent resident aliens who are members of the ACR or the ARHP may invest in RheumPAC.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Does RheumPAC make a difference?

It really does. Some legislative highlights brought to rheumatology through RheumPAC:

  1. MACRA Flexibility: RheumPAC and its partners successfully lobbied the CMS for options to avoid penalties.
  2. Flex IT: H.R. 5001 and S. 2822 allow providers in the Medicare EHR Incentive Program to report on a 90-day period in 2017 rather than a full calendar year.
  3. RheumPAC and its partners successfully defeated CMS’s Part B demonstration project, which would have reduced reimbursement to providers for expensive infusion treatments.
  4. Patients’ Access to Treatments Act (H.R. 2999): Reintroduced at the ACR’s urging.

On the state level, in 2016 we were instrumental in getting six biosimilars bills passed and four step therapy laws implemented, stopping a coverage change proposed by a payer in North Carolina for steroid injections and reversing a downcoding decision in the Palmetto MAC region.

Pages: 1 2 | Single Page

Filed Under: From the College, Legislation & Advocacy Tagged With: AC&R, Advocacy, American College of Rheumatology (ACR), Association of Rheumatology Professionals (ARP), Congress, FAQ, Legislation, political action committee, rheumatology, RheumPACIssue: September 2017

You Might Also Like:
  • What Is RheumPAC?
  • RheumPAC Advances Policy Issues of Rheumatology Professionals
  • RheumPAC: The Voice of the ACR
  • RheumPAC: How the ACR’s Non-Partisan Political Action Committee Works

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)